This paper re-imagines a world of abundance in the treatment of chronic diseases such as Tpe 2 Diabetes. It asks: what if preventive and diagnostic remedies were widely made available across the world, informed by the latest medical research? As Proof-of-Concept of a proposed solution, the paper describes the development and validation of a local Large Language Models (local-LLMs) based on Graph-based Retrieval-Augmented Generation (GraphRAG) for managing Gestational Diabetes Mellitus (GDM). The research thus seeks new insights into optimizing GDM treatment through a knowledge graph architecture, contributing to a deeper understanding of how artificial intelligence can extend medical expertise to underserved populations globally. The study employs an agile, prototyping approach utilizing GraphRAG to enhance knowledge graphs by integrating retrieval-based and generative artificial intelligence techniques. Training data was from academic papers published between January 2000 and May 2024 using the Semantic Scholar API and analyzed by mapping complex associations within GDM management to create a comprehensive knowledge graph architecture. It is categorically stated that, since the primary research objective was to establish the feasibility of a GraphRAG local-LLM PoC, no human subjects nor actual patient datasets were used. Empirical results indicate that the GraphRAG-based Proof of Concept outperforms open-source LLMs such as ChatGPT, Claude, and BioMistral across key evaluation metrics. Specifically, GraphRAG achieves superior accuracy with BLEU scores of 0.99, Jaccard similarity of 0.98, and BERT scores of 0.98, offering significant implications for personalized medical insights that enhance diagnostic accuracy and treatment efficacy. This research offers a novel perspective on applying GraphRAG-enabled LLM technologies to GDM management, providing valuable insights that extend current understanding of AI applications in healthcare. The study’s findings contribute to advancing the feasibility of GenAI for proactive GDM treatment and extending medical expertise to underserved populations globally.

The authors have declared no competing interest.

This research was supported by the Research Incentive Fund (RIF) Grant R22086 from Zayed University to AN, RS & EE.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes